Funding of PRRT (Lutate) in New South Wales

The Unicorn Foundation continues to advocate for greater access and funding for Peptide Receptor Radionuclide Therapy (PRRT).

In New South Wales, Dr John Leyden has been the consumer representative involved with the Agency of Clinical Innovations (ACI) Nuclear Medicine group development of 'Lutate therapy for NET patients in NSW' since 2010. The final submission was completed and submitted to the Minister for Health, Hon Jillian Skinner MP for consideration.

Dr John Leyden, on behalf of NSW NET cancer patients, met with NSW Health Senior Policy Advisor Cassandra Smith and ACI Chief Executive Dr Nigel Lyons to discuss the importance of and desperate need to fund Lutate in designated NSW public hospitals as per the proposal.

The Unicorn Foundation strongly urges all NSW NET patients, carers and friends to contact their local NSW Member of Parliament and request that they ask Health Minister Hon Jillian Skinner to fund Lutate therapy. We need this treatment and we need it now.

For more information to assist in this action, please contact Dr John Leyden at john.leyden@unicornfoundation.org.au

Share this article

Subscribe to our Newsletter

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Related News

Raising awareness of neuroendocrine cancer at Peninsula Bays Hospital Wellness Day

Raising Awareness for NETs on World Cancer Day in WA

Australia delivers excellent cancer care, but not equally

AUS-NET Update, January 2026

Walk, run, or ride this March4NETs!

For its third year, March4NETs will run throughout March 2026.

Get involved and support the 31,000 Australians living with neuroendocrine cancer.